Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 12
Submit an article Journal homepage
232
Views
6
CrossRef citations to date
0
Altmetric
Theme: Kidney Cancer - Reviews

Advanced kidney cancer: treating the elderly

Fable ZustovichIRCCS Istituto Oncologico Veneto, Medical Oncology, Via Gattamelata, 64-35128 Padua, ItalyCorrespondence[email protected]
&
Giacomo NovaraDepartment of Surgical, Oncological, and Gastroenterological Sciences, Urology Clinic, University of Padua, Padua, Italy
Pages 1389-1398 | Published online: 10 Jan 2014

References

  • Ferlay J, Autier P, Boniol M, Heanue M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581–592 (2007).
  • Lynch CF WM, Davila JA, PLatz CE. Cancer of the kidney and renal pelvis.
  • Nese N, Paner GP, Mallin K, Ritchey J et al. Renal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data Base. Ann. Diag. Pathol. 13, 1–8 (2009).
  • Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9, 179–186 (1969).
  • Denzinger S, Otto W, Burger M et al. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J. Surg. Oncol. 5, 16 (2007).
  • Mc Laughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin. Oncol. 33(5), 527–533 (2006).
  • Dutcher JP, Tannir N, Bellmunt J et al. Experience with sorafenib and the elderly patient. Med. Oncol. 27, 1359–1370 (2010).
  • Hutson TE, Bukowski RM, Cowey CL, Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77, 48–62 (2011).
  • Berger DA, Megwalu, II, Vlahiotis A et al. Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology 72, 359–363 (2008).
  • Bellmunt J, Negrier S, Escudier B et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit. Rev. Oncol. Hematol. 69, 64–72 (2009).
  • Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100, 1454–1463 (2008).
  • Kornblith AB, Kemeny M, Peterson BL et al. Survey of oncologists’ perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95, 989–996 (2002).
  • Yee KW, Pater JL, Pho L, Zee B, Siu LL. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J. Clin. Oncol. 21, 1618–1623.
  • Shuch B, La Rochelle JC, Wu J et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 113, 1324–1331 (2008).
  • Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655–1659 (2001).
  • Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966–970 (2001).
  • Flanigan RC, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071–1076 (2004).
  • Abdollah F, Sun M, Thuret R et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann. Surg. Oncol. 18, 2988–2996 (2011).
  • Sun M, Abdollah F, Schmitges J et al. Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. BJU Inter. 109, 1807–1812 (2012).
  • Sun M, Bianchi M, Karakiewicz PI et al. Reply to georgios papadopoulos, georgios stathouros, and konstantinos doumas’ letter to the editor re: Maxine Sun, Marco Bianchi, Jens Hansen et al. Chronic Kidney Disease After Nephrectomy in Patients with Small Renal Masses: A Retrospective Observational Analysis. 62, 696–703. Eur. Urol. 63(5), e65–e66 (2013).
  • Capitanio U, Zini L, Perrotte P et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology 1090–1095 (2008).
  • Krambeck AE, Leibovich BC, Lohse et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J. Urol. 1990–1995 (2006).
  • Guzzo TJ, Allaf ME, Pierorazio PM et al. Perioperative outcomes of elderly patients undergoing laparoscopic renal procedures. Urology 572–576 (2009).
  • Trinh QD, Bianchi M, Hansen J et al. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur. Urol. 1107–1114 (2013).
  • Choueiri TK, Schutz FA, Hevelone ND et al. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology 78, 93–98 (2011).
  • Powles T, Kayani I, Blank C et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol. 22, 1041–1047 (2011).
  • Chapin BF, Delacroix SE Jr, Culp SH et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol. 60, 964–971 (2011).
  • Richey SL, Culp SH, Jonasch E et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann. Oncol. 22, 1048–1053 (2011).
  • Margulis V, Shariat SF, Rapoport Y et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur. Urol. 63(5), 947–952 (2012).
  • De la Rosette JCS, van Poppel H. Old and Fragile Patients. In: Renal Cell Cancer.Springer, London, UK (2008).
  • Porta CBS, Beck J, Procopio G et al. Efficacy and safety of sorafenib in elderly patients, results from a large open label, non comparative phase III study in european patients with advanced RCC (EU-ARCCS). Ann. Oncol. 19, 596P (2008).
  • Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116, 1272–1280 (2010).
  • Jäger D KE, Zemanova M, Leonhartsberger N et al. PREDICT (Patient Characteristics in Renal Cell Carcinoma and Daily Practice Treatment with Sorafenib) global non-interventional study: final report. Eur. J. Cancer 48 (2011).
  • Procopio G, Bellmunt J, Dutcher J et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Brit. J. Cancer 108, 311–318 (2013).
  • Simonelli C FL, Giancalone A, Lleshi A et al. Sorafenib in elderly cancer patients with renal cell carcinoma: a single-institution experience. Presented at 2008 Genitourinary Cancers Symposium (abst 382).
  • Gernone A PA, Pagliarulo V. Comorbidity and sorafenib (SOR) therapy in elderly patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 29( Suppl. 7), Abstract 398 (2011).
  • Billemont B, Massard C, Negrier S et al. Antiangiogenic treatment in elderly patients (>75 years) with metastatic renal cell carcinoma (mRCC): experience from the French Renal Group. Presented at: 2010 Genitourinary Cancers Symposium. Abstract 364 (2010).
  • Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10, 757–763 (2009).
  • Hutson TB, R, Rini BI, Gore ME et al. A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 29 (2011).
  • Ugo De Giorgi KR, Giovanni Lo Re et al. Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer. J. Clin. Oncol. 30 (2012).
  • Brunello A, Basso U, Sacco C et al. Safety and activity of sunitinib in elderly patients (>=70 years) with metastatic renal cell carcinoma: a multicenter study. Ann. Oncol. 2012.
  • Porta C, Calvo E, Climent MA et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur. Urol. 61, 826–833 (2012).
  • Danesi R, Boni JP, Ravaud A. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications. Cancer Treat. Rev. 39(7), 784–792 (2013).
  • Grunwald V, Karakiewicz PI, Bavbek SE et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur. J. Cancer 48, 324–332 (2012).
  • van den Eertwegh AJ, Karakiewicz P, Bavbek S et al. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. Urology 81, 143–149 (2013).
  • Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256–4265 (2010).
  • Bajetta E RA, Bracarda S, Négrier S et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26 (2008).
  • Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28, 2137–2143 (2010).
  • Melichar B, Bracarda S, Matveev V et al. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann. Oncol. (2009) ( Epub ahead of print).
  • Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 356, 2271–2281 (2007).
  • Dutcher J SC, Tannir N, Escudier B. Correlation of survival with tumor histology, age and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon alpha. J. Clin. Oncol. 25 (2007).
  • Escudier B. Patient preference between pazopanib and sunitinib: Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. 2012 ASCO Annual Meeting. Abstract CRA4502. 2012.
  • Motzer RJ, Hutson TE, Reeves J. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. 2012 ESMO Congress. Abstract LBA8, 2012
  • Calvo E, Maroto P, del Muro XG et al. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 29(Suppl. 1), 11–20 (2010).
  • Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag. Res. 3, 273–285 (2011).
  • Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4462–4468 (2009).
  • Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378, 1931–1939 (2011).
  • Aapro MS. The frail are not always elderly. J. Clin. Oncol. 23, 2121–2122 (2005).
  • Passage KJ, McCarthy NJ. Critical review of the management of early-stage breast cancer in elderly women. Int. Med. J. 37, 181–189 (2007).
  • Katz S, Akpom CA. A measure of primary sociobiological functions. Inter. J. Health Ser. 6, 493–508.
  • Coebergh JW, Janssen-Heijnen ML, Post PN et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J. Clin. Epidemiol. 52, 1131–1136 (1999).
  • Extermann M. Interaction between comorbidity and cancer. Cancer Control 14, 13–22 (2007).
  • Bellmunt J, Fishman M, Eisen T et al. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev. Anticancer Ther. 10, 825 (2010).
  • Motzer RJ, Hutson TE, Olsen MR et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J. Clin. Oncol. 30(12), 1371–1377 (2012).
  • Eisen T, Oudard S, Szczylik C et al. Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: Subgroup analysis of The Approaches in Renal Cancer Global Evaluation Trial (TARGETs). 2007 European Association of Urology Annual Meeting. Abstract 964 (2007).
  • Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst. 100, 1454–1463 (2008).
  • Bukowski RM, Stadler WM, Figlin RA et al. Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: a subset analysis from the Advanced renal cell carcinoma sorafenib (ARCCS) expanded access program in North America. J. Clin. Oncol. 26(15), Abstract 5045 (2008).
  • Sternberg CN, Davis ID Mardiak J et al.Pazopanib in Locally Advanced or Metastatic Renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).
  • Rini B, Escudier B, Tomczak P et al.Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. 2011 ASCO Meeting. Abstract 4503 (2007).
  • Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103–2111 (2007).
  • Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422–5428 (2008).
  • Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271–2281 (2007).
  • Osanto S, Hutson TE, Calvo E et al. Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 28(15), Abstracts 4608 (2010).
  • Bellmunt J, Négrier S, Escudier B et al. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit. Rev. Oncol. Hematol. 69(1), 64–72 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.